MiPet Easecto Europeiska unionen - lettiska - EMA (European Medicines Agency)

mipet easecto

zoetis belgium sa - sarolaners - ekoparasiticīdi sistēmiskai lietošanai - suņi - par attieksmi pret ērču invāzijas (dermacentor reticulatus, ixodes hexagonus,ixodes ricinus un rhipicephalus sanguineus). veterinārām zālēm ir tūlītēja un pastāvīga ērču nogalināšanas darbība vismaz 5 nedēļas. blusu invāzijas ārstēšanai (ctenocephalides felis un ctenocephalides canis). veterinārmedicīniskajām zālēm ir tūlītēja un pastāvīga bloķēšanas darbība pret jaunām invāzijām vismaz 5 nedēļas. Šīs veterinārās zāles var izmantot kā ārstēšanas stratēģiju blusu alerģiskā dermatīta (fad) ārstēšanai.. sarkticas mange (sarcoptes scabiei) ārstēšanai. lai ārstētu ausu ērces invāzijas (otodectes cynotis). demodikozes (demodex canis) ārstēšanai. blusas un ērces ir jāpievieno mītnes un sāk barot, lai būtu pakļauti aktīvās vielas.

Rozlytrek Europeiska unionen - lettiska - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiski līdzekļi - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Teysuno Europeiska unionen - lettiska - EMA (European Medicines Agency)

teysuno

nordic group b.v. - ftorafūrs, gimeracil, oteracil - kuņģa-zarnu trakta traucējumi - antineoplastiski līdzekļi - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Padcev Europeiska unionen - lettiska - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiski līdzekļi - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Akeega Europeiska unionen - lettiska - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.